Key clinical point: Adding palbociclib to ibrutinib appears to produce more complete responses in previously treated patients with MCL than was seen with ibrutinib alone.
Major finding: The complete response rate for the combination treatment was 37%.
Study details: A prospective, phase 1 trial of 27 patients with previously treated MCL.
Disclosures: The trial was sponsored by the National Cancer Institute. Funding was provided by the Sarah Cannon Fund at the HCA Foundation. The investigators reported financial relationships with Janssen, Gilead, AstraZeneca, Celgene, Karyopharm, and others.
Martin P et al. Blood. 2019 Jan 28. doi: 10.1182/blood-2018-11-886457.